- Exchange: Frankfurt
- Sector: Consumer, Non-cyclical
- Industry: Healthcare-Products
- Sub-Industry: Medical Instruments
Snapshot for Delcath Systems Inc (DV3)
| Open: | 0.299 | Day's Range: | 0.280 - 0.299 | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 0.280 | 52wk Range: | 0.277 - 2.000 | 1-Yr Rtn: | -76.92% |
Key Statistics for DV3
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | -0.4220 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 4,647 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for DV3
Company Profile & Key Executives for DV3
Delcath Systems Inc. has developed a system to isolate the liver from the circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. This system filters the patients blood removing most of the harmful chemotherapy agents lessening the side-effects of the treatment.
| Eamonn P HobbsPresident/CEO | Graham G MiaoExec VP/CFO |
| Peter James GrahamExec VP/Chief Compliance Ofcr | Jennifer SimpsonExec VP/Global Head:Bus Ops |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
DV3 News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page